Loading page
Loading page
Loading substance route
Classified as habit-forming. Psychological dependence may develop with regular use, similar to other synthetic cannabinoids.
Deaths have occurred from overdose. The extremely high potency of AB-FUBINACA significantly increases overdose risk compared to other cannabinoids. Its use has been linked to numerous hospitalizations and several deaths, with some mass overdose events involving over 100 individuals requiring emergency medical transport.
AB-FUBINACA was initially synthesized by Pfizer in 2009 during research into novel analgesic compounds. The pharmaceutical company never advanced the substance to human clinical trials, and it was subsequently abandoned as a potential medication.…
UNODC Schedule II (recommended December 2019)
Classified as a controlled substance since October 2015 under national drug control regulations. Manufacturing, trafficking, and possession are subject to legal penalties.
Listed as an Anlage II controlled substance under the Betäubungsmittelgesetz since November 2014. This classification permits restricted medical and scientific use under license.
Scheduled in a government decree on psychoactive substances prohibited from the consumer market, effective 19 October 2017. Production, import, sale, and possession for sale are prohibited.
Designated as a Schedule I controlled substance in January 2014. Classified as having high abuse potential with no accepted medical use under the Controlled Substances Act.
11 sources cited